Don't know about $30-$35 without positive news...but
IMO extremely oversold with $8.33 per share in cash ($450M) and the ability to license/acquire compound with pipeline in UC/UP Chrones as well as Skin Infection indication from another company which is on the runway with PhaseII/III and Phase III but without the funds to move expeditiously ... a licensing opportunity in the offing?
IMO see a rebound to $12-$15 for starters...after those funds/investors are finished booking losses to offset gains in 2021 and those with Margin calls who haven't liquidate finish doing so. We could have seen the low from booking loses and Margin liquidation at the eod and down to $8.50. IMO likely hit bottom today...but could retest tomorrow